Effect of Angiotensin Receptor blockers on Insulin Resistance in End Stage Renal Disease Patients with Maintenance Hemodialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20130901001

Enrollment

Registered

2013-09-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease insulin resistance insulin hypersensitivity kidney disease angiotensin receptor blocker

Interventions

Active Comparator Drug,Placebo Comparator Drug

Valsartan,Non RAAS blockers

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age> 18 year Chronic hemodialysis at least 3 months Adequate dialysis with spKt/V>1.2 and 3 time per weeks No insulin treatment

Exclusion criteria

Exclusion criteria: all malignancy active infection congestive heart failure FC III-IV recent cardiovascular disease or cerebrovascular disease with 3 months

Design outcomes

Primary

Measure	Time frame
insulin resistance 12 week HOMA-IR	—

Secondary

Measure	Time frame
glucose metabolism 12 weeks fasting plasma glucose	—

Countries

Thailand

Contacts

Public Contactbancha satirapoj

Phramongkutklao hospital

satirapoj@yahoo.com026444676

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026